Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis. oleh Luke E Barry, Grainne E Crealey, Paul Cockwell, Stephen J Elliman, Matthew D Griffin, Alexander P Maxwell, Timothy O'Brien, Norberto Perico, Ciaran O'Neill